Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. (PSTX): 12 pipeline candidates · ~71 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
71.2 months
D/E 2.37 · 1% dilution
Lead: Phase 1
12 candidates
N/A
N/A
A transparent, data-derived signal for Poseida Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$49.3M
Quarterly Burn
$9.6M
Runway
71.2 mo
Revenue
$71.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| p-bcma-allo1 | Phase 1 |
| p-bcma-allo1 car-t cells | Phase 1 |
| p-bcmacd19-allo1 | Phase 1 |
| p-cd19cd20-allo1 | Phase 1 |
| p-cd70-allo1 | Phase 1 |
| p-fviii-101 | Preclinical |
| p-muc1c-allo1 | Phase 1 |
| p-muc1c-allo1 car-t cells | Phase 1 |
| p-otc-101 | Preclinical |
| p-psma-allo1 | Preclinical |
Showing 10 of 12 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Poseida Therapeutics, Inc.'s pipeline?
Poseida Therapeutics, Inc. (PSTX) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Poseida Therapeutics, Inc.'s lead drug candidate?
Poseida Therapeutics, Inc.'s most advanced tracked candidate is p-bcma-allo1 (Phase 1) for Multiple Myeloma.
What is Poseida Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Poseida Therapeutics, Inc. has approximately 71.2 months of cash runway.
Who is the CEO of Poseida Therapeutics, Inc.?
Kristin Yarema, Ph.D. is the chief executive officer of Poseida Therapeutics, Inc. (PSTX).
Get the full picture on Poseida Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.